A Blood Pressure Drug Just Slowed Lung Scarring. Wait, What?

Boehringer Ingelheim's nerandomilast (a PDE4B inhibitor) broke through in October 2025, becoming the first novel-mechanism drug approved for IPF in years. But the field still desperately needs more arrows in the quiver. Each new mechanism that works gives doctors another card to play, potentially in combination.

That's why inhaled treprostinil is generating so much excitement. It's not just another pill working through the same tired pathways. It's an entirely different approach.

From Blood Vessels to Scar Tissue

The repurposing story here is genuinely clever. In pulmonary arterial hypertension, treprostinil works by relaxing blood vessels, preventing clots, and stopping smooth muscle cells from overgrowing. It's a prostacyclin analog, meaning it mimics a natural molecule your body uses to keep blood vessels healthy.

But scientists noticed something interesting in the lab. When they exposed lung fibroblasts (the cells responsible for making scar tissue) to treprostinil, those cells slowed their proliferation, produced less collagen, and resisted transforming into the aggressive myofibroblasts that drive fibrosis. The drug was hitting multiple antifibrotic targets through IP, EP2, and DP1 receptor pathways, all linked to a signaling molecule called cAMP.

Think of it like discovering that your car's windshield washer fluid also works as an excellent stain remover. Same product, completely different use case, surprisingly effective.

The fact that treprostinil is inhaled matters, too. Delivering the drug directly to the lungs means high local concentrations where the scarring is happening, with less systemic exposure. It's targeted therapy without needing a targeted molecule.

The Safety Question (And Why It's Not a Dealbreaker)

No drug is perfect. The most common side effect was cough, which tracks with what doctors already know about prostacyclin-class drugs. There were no new safety signals, and the profile was consistent with years of Tyvaso use in other lung conditions.

That said, cough is a tricky side effect in a disease that already makes breathing miserable. Discontinuation rates were higher with treprostinil than placebo. For some patients, the treatment burden of nebulizing a drug multiple times daily while dealing with cough could be a real barrier. It's worth watching how this plays out in practice.

The Competitive Landscape Is Getting Crowded

United Therapeutics isn't operating in a vacuum. The IPF pipeline has exploded, with one recent analysis counting 150 unique programs in development. Beyond the newly approved nerandomilast, Bristol Myers Squibb's admilparant (targeting the LPA1 pathway) is in Phase 3 with data expected soon. PureTech Health's deupirfenidone, a next-generation version of the older pirfenidone, is also entering late-stage trials.

But inhaled treprostinil has a meaningful head start. The FDA has already accepted United Therapeutics' supplemental new drug application (sNDA) for this indication as of September 2026. That puts the drug on a clear regulatory timeline while most competitors are still collecting data.

If approved, treprostinil would become the first inhaled antifibrotic therapy for IPF. That's a differentiated position in a market that has historically relied on oral drugs with significant side effects and modest efficacy.

The Billion-Dollar "So What"

For United Therapeutics, the commercial implications are enormous. Tyvaso already generates substantial revenue from pulmonary hypertension. Adding IPF to the label would dramatically expand the addressable market, bringing in a large patient population that currently has few options.

For IPF patients, this is something more important than a stock catalyst. It's a fundamentally new way to fight a disease that has been winning for far too long. Two large, well-run trials showed consistent, statistically significant preservation of lung function. The safety profile is manageable. The regulatory path is open.

The plumber, it turns out, makes an excellent pastry chef.

Novartis Is Shrinking in Switzerland to Get Bigger Everywhere Else

Novartis is cutting 130 jobs and closing a Basel biologics site, but the real story is much bigger. The pharma giant is part of an industry-wide manufacturing reshuffling that's rewriting the map of where drugs get made.